en · de · es · fr · pt
cjc-1295-notes.peptides5388.com › Topic › Background And Naming Conventions — Quick Reference

Background And Naming Conventions — Quick Reference

By Editorial Desk · published 2026-04-26 · last reviewed 2026-06-15 · Topic

DAC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

Compound Identity and Development History

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Related pages on this site

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Reference notes

== History == FT-ICR was invented by Melvin B. Comisarow and Alan G. Marshall at the University of British Columbia. The first paper appeared in Chemical Physics Letters in 1974. The inspiration was earlier developments in conventional ICR and Fourier-transform nuclear magnetic resonance (FT-NMR) spectrometry. Marshall has continued to develop the technique at The Ohio State University and Florida State University.

Phenazopyridine is a medication which, when excreted by the kidneys into the urine, has a local analgesic effect on the urinary tract. It is often used to help with the pain, irritation, or urgency caused by urinary tract infections, surgery, or injury to the urinary tract. In 2023, it was the 275th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.

include 187Re, 194Os, 210Pb, 212At, 227Ac, 228Ra, 241Pu, 247Cm, 250Cm, and 249Bk. The following table lists theoretically-possible bound-state β− transitions for these nuclides, among which some transitions are impossible for neutral atoms.

=== IATSE strike === Problems kept coming on July 16, when thirty to thirty-five crew members went on strike to demand better wages and benefits, under encouragement from the IATSE union, whose local representative warned that the dispute would cost The Stone Group an additional $40,000 per day. The production was sanctioned by the Directors Guild of America and Screen Actors Guild, but did not recognize other labor groups. As such, the film's technicians were signed to a flat fee. Filming was again suspended but, since Mississippi was a right-to-work state, the concerned workers were summarily fired and fifty new ones were brought in. This included cinematographer Leonetti, who was replaced by Alexander Gruszynski and complained that he stood to lose $50,000 in wages. Meanwhile, on July 17, Bosworth was officially released from his NFL contract by the Seattle Seahawks, although this was expected due to his persistent shoulder issues, and he already considered himself an actor first.

Sources: en.wikipedia.org

Notes from published material

== Society and culture == According to the parasite-stress theory of sociality, examined in a 2009 review by Nettle, several studies have reported associations between regional pathogen load and aspects of human social behavior. Proponents of the theory link higher pathogen load to smaller ethnic and religious group sizes, more restricted sexual behavior, stronger mate preferences for apparent health, higher fertility with reduced per-child parental investment, increased prevalence of polygyny, and greater collectivism relative to individualism. They attribute these patterns to strategies that may limit pathogen transmission or offset higher mortality. Nettle's review notes that alternative explanations exist for several of these associations, and that some of those alternative factors may themselves ultimately trace back to pathogen load. This body of research is largely correlational and is best understood as a proposed explanatory framework rather than an established causal mechanism.

=== Bosnian War === Hitchens cited the Bosnian War as monumentally changing his views on military intervention, commenting that for the first time he found himself on the side of neoconservatives. In an interview with Johann Hari he said:

== Science and technology == Net protein utilization, the percentage of ingested nitrogen retained in the body NPU terminology (Nomenclature for Properties and Units), for the clinical laboratory sciences

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network